Methylation analysis in spontaneous sputum for lung cancer diagnosis

Lung Cancer

Volumn 84, Issue 2, 2014, Pages 127-133

  Hubers, A Jasmijn ^a   van der Drift, Miep A ^b   Prinsen, Clemens F M ^c   Witte, Birgit I ^a   Wang, Yinghui ^d   Shivapurkar, Narayan ^e,f   Stastny, Victor ^e   Bolijn, Anne S ^a,c   Hol, Bernard E A ^c   Feng, Ziding ^d   Dekhuijzen, P N Richard ^b   Gazdar, Adi F ^e   Thunnissen, Erik ^c  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c CANISIUS WILHELMINA HOSPITAL   (Netherlands)

^d Fred Hutchinson Cancer Research Center   (United States)

^e UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^f GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Biomarkers; Diagnosis; Early detection; Epigenetics; Methylation; Non small cell lung cancer; Sputum

Indexed keywords

AGED; APC GENE; ARTICLE; CANCER PATIENT; CONTROLLED STUDY; CYGB GENE; DEVELOPED COUNTRY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DNA MARKER; DNA METHYLATION; FATALITY; FEMALE; HIGH RISK PATIENT; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; ONCOGENE; PRIORITY JOURNAL; RASSF1A GENE; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; SPUTUM CYTODIAGNOSIS; CARCINOMA, SQUAMOUS CELL; CASE CONTROL STUDY; EARLY DIAGNOSIS; GENETICS; LUNG NEOPLASMS; METABOLISM; MIDDLE AGED; MULTIVARIATE ANALYSIS; RECEIVER OPERATING CHARACTERISTIC; RISK; SPUTUM;

APC PROTEIN; APC PROTEIN, HUMAN; CYTOGLOBIN; GLOBIN; RASSF1 PROTEIN, HUMAN; TUMOR MARKER; TUMOR SUPPRESSOR PROTEIN;

ADENOMATOUS POLYPOSIS COLI PROTEIN; AGED; CARCINOMA, SQUAMOUS CELL; CASE-CONTROL STUDIES; DNA METHYLATION; EARLY DETECTION OF CANCER; FEMALE; GLOBINS; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; RISK; ROC CURVE; SPUTUM; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEINS;

EID: 84899478253     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2014.01.019     Document Type: Article

References (38)

1. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012, 62:10-29.
2. Rivera M.P., Mehta A.C., Wahidi M.M. Establishing the diagnosis of lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2013, 143:e142S-e165S.
3. Thunnissen F.B.J.M. Sputum examination for early detection of lung cancer. J Clin Pathol 2003, 56:805-810.
4. Bechtel J.J., Kelley W.R., Petty T.L., Patz D.S., Saccomanno G. Outcome of 51 patients with roentgenographically occult lung cancer detected by sputum cytologic testing: a community hospital program. Arch Intern Med 1994, 154:975-980.
5. Somers V.A., Pietersen A.M., Theunissen P.H., Thunnissen F.B. Detection of K-ras point mutations in sputum from patients with adenocarcinoma of the lung by point-EXACCT. J Clin Oncol 1998, 16:3061-3068.
6. Destro A., Bianchi P., Alloisio M., Laghi L., Di Gioia S., Malesci A., et al. K-ras and p16(INK4A)alterations in sputum of NSCLC patients and in heavy asymptomatic chronic smokers. Lung Cancer 2004, 44:23-32.
7. Esteller M. Epigenetic changes in cancer. F1000 Biol Rep 2011, 3:9.
8. Belinsky S.A., Liechty K.C., Gentry F.D., Wolf H.J., Rogers J., Vu K., et al. Promoter hypermethylation of multiple genes in sputum precedes lung cancer incidence in a high-risk cohort. Cancer Res 2006, 66:3338-3344.
9. Konno S., Morishita Y., Fukasawa M., Shu Y., Wang D., Tanaka R., et al. Anthracotic index and DNA methylation status of sputum contents can be used for identifying the population at risk of lung carcinoma. Cancer 2004, 102:348-354.
10. Olaussen K.A., Soria J.-C., Park Y.W., Kim H.J., Kim S.H., Ro J.Y., et al. Assessing abnormal gene promoter methylation in paraffin-embedded sputum from patients with NSCLC. Eur J Cancer 2005, 41:2112-2119.
11. Palmisano W.A., Divine K.K., Saccomanno G., Gilliland F.D., Baylin S.B., Herman J.G., et al. Predicting lung cancer by detecting aberrant promoter methylation in sputum. Cancer Res 2000, 60:5954-5958.
12. Shivapurkar N., Stastny V., Okumura N., Girard L., Xie Y., Prinsen C., et al. Cytoglobin, the newest member of the globin family, functions as a tumor suppressor gene. Cancer Res 2008, 68:7448-7456.
13. Shivapurkar N., Stastny V., Suzuki M., Wistuba I.I., Li L., Zheng Y., et al. Application of a methylation gene panel by quantitative PCR for lung cancers. Cancer Lett 2007, 247:56-71.
14. Shivapurkar N., Stastny V., Xie Y., Prinsen C., Frenkel E., Czerniak B., et al. Differential methylation of a short CpG-rich sequence within exon 1 of TCF21 gene: a promising cancer biomarker assay. Cancer Epidemiol Biomarkers Prev 2008, 17:995-1000.
15. Van der Drift M.A., Prinsen C.F.M., Hol B.E.A., Bolijn A.S., Jeunink M.A.F., Dekhuijzen P.N.R., et al. Can free DNA be detected in sputum of lung cancer patients?. Lung Cancer 2008, 61:385-390.
16. Hsu H.-S., Chen T.-P., Wen C.-K., Hung C.-H., Chen C.-Y., Chen J.-T., et al. Multiple genetic and epigenetic biomarkers for lung cancer detection in cytologically negative sputum and a nested case-control study for risk assessment. J Pathol 2007, 213:412-419.
17. Belinsky S.A., Klinge D.M., Dekker J.D., Smith M.W., Bocklage T.J., Gilliland F.D., et al. Gene promoter methylation in plasma and sputum increases with lung cancer risk. Clin Cancer Res 2005, 11:6505-6511.
18. Belinsky S.A., Grimes M.J., Casas E., Stidley C.A., Franklin W.A., Bocklage T.J., et al. Predicting gene promoter methylation in non-small-cell lung cancer by evaluating sputum and serum. Br J Cancer 2007, 96:1278-1283.
19. Hubers A.J., Prinsen C.F.M., Sozzi G., Witte B.I., Thunnissen E. Molecular sputum analysis for the diagnosis of lung cancer. Br J Cancer 2013, 109:530-537.
20. Pepe M.S., Feng Z., Janes H., Bossuyt P.M., Potter J.D. Pivotal evaluation of the accuracy of a biomarker used for classification or prediction: standards for study design. J Natl Cancer Inst 2008, 100:1432-1438.
21. Global strategy for the diagnosis, management, and prevention of COPD. Glob. Initiat. Chronic Obstr. Lung Dis. 2006.
22. Byers T., Wolf H.J., Franklin W.A., Braudrick S., Merrick D.T., Shroyer K.R., et al. Sputum cytologic atypia predicts incident lung cancer: defining latency and histologic specificity. Cancer Epidemiol Biomarkers Prev 2008, 17:158-162.
23. Costantino J.P., Gail M.H., Pee D., Anderson S., Redmond C.K., Benichou J., et al. Validation studies for models projecting the risk of invasive and total breast cancer incidence. J Natl Cancer Inst 1999, 91:1541-1548.
24. Tang M., Torres-Lanzas J., Lopez-Rios F., Esteller M., Sanchez-Cespedes M. Wnt signaling promoter hypermethylation distinguishes lung primary adenocarcinomas from colorectal metastasis to the lung. Int J Cancer 2006, 119:2603-2606.
25. Oleksiewicz U., Liloglou T., Tasopoulou K.-M., Daskoulidou N., Bryan J., Gosney J.R., et al. Cytoglobin has bimodal - tumour suppressor and oncogene functions in lung cancer cell lines. Hum Mol Genet 2013, 22(16):3207-3217.
26. Hesson L.B., Cooper W.N., Latif F. The role of RASSF1A methylation in cancer. Dis Markers 2007, 23:73-87.
27. Honorio S., Agathanggelou A., Schuermann M., Pankow W., Viacava P., Maher E.R., et al. Detection of RASSF1A aberrant promoter hypermethylation in sputum from chronic smokers and ductal carcinoma in situ from breast cancer patients. Oncogene 2003, 22:147-150.
28. Liu Y., Lan Q., Shen M., Jin J., Mumford J., Ren D., et al. Aberrant gene promoter methylation in sputum from individuals exposed to smoky coal emissions. Anticancer Res 2008, 28:2061-2066.
29. Young R.P., Hopkins R.J., Gamble G.D. Clinical applications of gene-based risk prediction for lung cancer and the central role of chronic obstructive pulmonary disease. Front Genet 2012, 3:210.
30. Field J.K., Brambilla C., Caporaso N., Flahault A., Henschke C., Herman J., et al. Consensus statements from the Second International Lung Cancer Molecular Biomarkers Workshop: a European strategy for developing lung cancer molecular diagnostics in high risk populations. Int J Oncol 2002, 21:369-373.
31. Leng S., Do K., Yingling C.M., Picchi M.a., Wolf H.J., Kennedy T.C., et al. Defining a gene promoter methylation signature in sputum for lung cancer risk assessment. Clin Cancer Res 2012, 18:3387-3395.
32. Kennedy T.C., Proudfoot S.P., Piantadosi S., Wu L., Saccomanno G., Petty T.L., et al. Efficacy of two sputum collection techniques in patients with air flow obstruction. Acta Cytol 1999, 43:630-636.
33. Baryshnikova E., Destro A., Infante M.V., Cavuto S., Cariboni U., Alloisio M., et al. Molecular alterations in spontaneous sputum of cancer-free heavy smokers: results from a large screening program. Clin Cancer Res 2008, 14:1913-1919.
34. Belinsky S.A., Palmisano W.A., Gilliland F.D., Crooks L.A., Divine K.K., Winters S.A., et al. Aberrant promoter methylation in bronchial epithelium and sputum from current and former smokers. Cancer Res 2002, 62:2370-2377.
35. Cirincione R., Lintas C., Conte D., Mariani L., Roz L., Vignola A.M., et al. Methylation profile in tumor and sputum samples of lung cancer patients detected by spiral computed tomography: a nested case-control study. Int J Cancer 2006, 118:1248-1253.
36. Leng S., Stidley C.A., Willink R., Bernauer A., Do K., Picchi M.A., et al. Double-strand break damage and associated DNA repair genes predispose smokers to gene methylation. Cancer Res 2008, 68:3049-3056.
37. Stidley C.A., Picchi M.A., Leng S., Willink R., Crowell R.E., Flores K.G., et al. Multivitamins, folate, and green vegetables protect against gene promoter methylation in the aerodigestive tract of smokers. Cancer Res 2010, 70:568-574.
38. Zöchbauer-Müller S., Lam S., Toyooka S., Virmani A.K., Toyooka K.O., Seidl S., et al. Aberrant methylation of multiple genes in the upper aerodigestive tract epithelium of heavy smokers. Int J Cancer 2003, 107:612-616.